GlassScriptPhysician profile
Tariq Mahmood
NPI 1104874171
$24,414.84
in general payments reported to CMS, 2019-2025
88 companies · $5,321 in 2025
The $5,321 reported for 2025 was more than what 83% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,261 · 2020: $2,229 · 2021: $3,384 · 2022: $2,927 · 2023: $3,656 · 2024: $4,637 · 2025: $5,321.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13K · Education: $240.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $13,373.69 |
| Education | $239.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,880.92 | 2019-2025 | Calquence, Lynparza, Imfinzi |
| Celgene Corporation | $1,574.72 | 2019-2025 | Reblozyl, Pomalyst, Opdivo |
| Incyte Corporation | $1,470.57 | 2019-2025 | Monjuvi, Jakafi, Pemazyre |
| Pfizer INC. | $1,409.19 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $1,232.13 | 2019-2025 | Keytruda, Welireg, Lynparza |
| Janssen Biotech, INC. | $1,094.80 | 2019-2025 | Rybrevant, Erleada, Tecvayli |
| Novartis Pharmaceuticals Corporation | $1,070.42 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $991.06 | 2019-2025 | Opdivo, Opdualag |
| Pharmacyclics LLC, An Abbvie Company | $816.14 | 2019-2023 | Imbruvica |
| Abbvie INC. | $714.90 | 2019-2025 | |
| Daiichi Sankyo INC. | $706.95 | 2020-2025 | Enhertu, Vanflyta, Datroway |
| Eisai INC. | $622.64 | 2020-2025 | |
| Amgen INC. | $588.80 | 2019-2025 | Lumakras, Nplate, Xgeva |
| Glaxosmithkline, LLC. | $572.22 | 2020-2025 | Ojjaara, Jemperli, Zejula |
| Lilly USA, LLC | $566.99 | 2019-2024 | Jaypirca, Verzenio, Retevmo |
Show all 86 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $565.36 | 2019-2025 | Tukysa, Padcev, Adcetris |
| Genzyme Corporation | $526.10 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $498.85 | 2019-2025 | Alunbrig, Fruzaqla, Ninlaro |
| Genentech USA, INC. | $438.02 | 2019-2025 | Polivy, Tecentriq, Phesgo |
| Exelixis INC. | $409.12 | 2020-2025 | Cabometyx |
| Karyopharm Therapeutics INC. | $400.44 | 2020-2025 | Xpovio |
| Bayer Healthcare Pharmaceuticals INC. | $392.79 | 2019-2025 | |
| Gilead Sciences, INC. | $334.93 | 2021-2025 | Trodelvy |
| Puma Biotechnology, INC. | $331.96 | 2019-2025 | |
| Aveo Pharmaceuticals, INC. | $290.27 | 2021-2025 | Fotivda |
| Alexion Pharmaceuticals, INC. | $283.01 | 2022-2025 | Ultomiris |
| Boehringer Ingelheim Pharmaceuticals, INC. | $274.08 | 2019-2025 | Gilotrif |
| Array Biopharma INC | $271.65 | 2024-2025 | Mektovi, Braftovi, Tukysa |
| Sobi, INC | $228.47 | 2022-2025 | |
| Ipsen Biopharmaceuticals, INC | $216.08 | 2020-2024 | Onivyde, Somatuline Depot |
| Emd Serono, INC. | $209.75 | 2021-2025 | Bavencio |
| Blueprint Medicines Corporation | $206.10 | 2021-2025 | Ayvakit |
| Coherus Oncology, INC. | $193.19 | 2021-2025 | Loqtorzi |
| Beigene USA, INC. | $190.98 | 2022-2024 | Brukinsa |
| Regeneron Healthcare Solutions, INC. | $184.64 | 2021-2025 | Libtayo |
| Stemline Therapeutics INC. | $172.65 | 2023-2025 | Orserdu, Elzonris |
| Astellas Pharma US INC | $171.30 | 2019-2024 | Padcev |
| Adc Therapeutics America, INC. | $156.96 | 2022-2025 | |
| Taiho Oncology, INC. | $142.32 | 2020-2025 | |
| Genmab U.S., INC. | $116.53 | 2023-2025 | Epkinly |
| Amag Pharmaceuticals, INC. | $109.50 | 2020-2021 | |
| Aurobindo Pharma USA, INC. | $107.55 | 2019-2020 | |
| Kite Pharma, INC. | $93.32 | 2020-2024 | Yescarta |
| Agios Pharmaceuticals, INC. | $79.88 | 2019-2023 | Pyrukynd |
| Pharmaessentia USA Corporation | $79.65 | 2024-2025 | Besremi |
| Csl Behring | $73.82 | 2023-2025 | Idelvion, Afstyla |
| Accord Healthcare, INC. | $71.32 | 2023-2025 | |
| Immunogen, INC. | $63.69 | 2023 | Elahere |
| Rigel Pharmaceuticals, INC. | $61.92 | 2020-2025 | Rezlidhia, Tavalisse, Gavreto |
| Morphosys, US INC. | $59.48 | 2021-2023 | Monjuvi |
| Servier Pharmaceuticals LLC | $56.00 | 2021-2024 | |
| Immunocore Limited | $54.11 | 2024 | Kimmtrak |
| Acrotech Biopharma INC. | $52.37 | 2021-2022 | |
| Pharmacosmos Therapeutics INC. | $50.80 | 2025 | Monoferric |
| Epizyme, INC. | $49.43 | 2021-2022 | |
| Recordati_rare_diseases_inc. | $47.55 | 2024-2025 | Sylvant, Enjaymo |
| Deciphera Pharmaceuticals INC. | $47.23 | 2021-2024 | Qinlock |
| Verastem, INC. | $43.85 | 2019 | |
| Clovis Oncology, INC. | $41.95 | 2019-2020 | |
| Tg Therapeutics, INC. | $40.81 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $36.50 | 2022 | |
| Iovance Biotherapeutics, INC. | $34.80 | 2025 | Amtagvi |
| Acceleron Pharma, INC. | $32.49 | 2021 | |
| Dova Pharmaceuticals | $29.72 | 2020-2021 | |
| Tempus Ai, INC | $28.84 | 2024 | |
| Jazz Pharmaceuticals INC. | $28.37 | 2025 | |
| Syndax Pharmaceuticals, INC. | $28.16 | 2025 | |
| Eusa Pharma (US) LLC | $26.47 | 2021 | |
| Ge Healthcare | $25.47 | 2025 | |
| Dendreon Pharmaceuticals LLC | $25.09 | 2023 | Provenge |
| Myriad Genetic Laboratories, INC. | $25.05 | 2020 | |
| Beone Medicines USA, INC. | $23.62 | 2025 | Brukinsa |
| Caris Mpi, INC. | $22.92 | 2025 | Mi Cancer Seek |
| Cti Biopharma Corp. | $22.27 | 2023 | Vonjo |
| Apellis Pharmaceuticals, INC. | $21.61 | 2023 | Empaveli |
| Immunomedics, INC. | $20.99 | 2020 | |
| Foundation Medicine, INC. | $20.84 | 2019 | |
| G1 Therapeutics, INC. | $20.05 | 2023 | Cosela |
| Sanofi-Aventis U.S. LLC | $19.58 | 2021 | |
| Geron Corporation | $18.67 | 2025 | Rytelo |
| Secura Bio, INC. | $18.24 | 2024 | Copiktra |
| Cumberland Pharmaceuticals, INC. | $18.10 | 2023 | Sancuso |
| Novocure INC. | $18.02 | 2020 | |
| Advanced Accelerator Applications | $17.35 | 2019 | |
| Sirtex Medical INC | $16.55 | 2023 | Sir-Spheres Microspheres |
| Mirati Therapeutics, INC. | $12.84 | 2023 | Krazati |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
Reblozyl $742Enhertu $560Keytruda $549Lynparza $456Calquence $427Imbruvica $377Opdivo $369Epkinly $356Cabometyx $337Monjuvi $336Imfinzi $319Kisqali $302Jakafi $291Braftovi $272Mektovi $272Tukysa $268Lenvima $266Padcev $262Ultomiris $261Opdualag $246Inlyta $243Fotivda $216Xpovio $216Alunbrig $215Elrexfio $201Adcetris $199Welireg $193Elahere $189Rybrevant $189Ojjaara $179Fabhalta $175Nubeqa $171Jemperli $166Ayvakit $165Pemazyre $162Zejula $160Orserdu $154Sarclisa $154Xtandi $151Trodelvy $149Erleada $146Pomalyst $136Brukinsa $135Bosulif $125Libtayo $121Doptelet $117Lonsurf $110Inqovi $110Tecvayli $109Zynyz $108Fruzaqla $106Vanflyta $106Darzalex $105Talzenna $102Polivy $101Lorbrena $92.18Talvey $85.48Tivdak $85.00Tecentriq $83.71Gilotrif $81.95Jaypirca $81.92Xofigo $79.79Lutathera $79.69Besremi $79.65Somatuline Depot $79.52Onivyde $79.52Carvykti $78.68Phesgo $74.61Idelvion $73.82Afstyla $73.82Nerlynx $73.53Camcevi $71.32Ibrance $70.63Tagrisso $67.28Vonjo $65.48Balversa $65.21Venclexta $63.72Verzenio $58.51Datroway $56.73Pluvicto $56.60Synagis $55.06Kimmtrak $54.11Bavencio $52.95Scemblix $52.18Monoferric $50.80Wayrilz $45.48Stivarga $44.00Vitrakvi $44.00Akeega $43.73Ninlaro $42.54Besponsa $42.15Iclusig $41.64Yescarta $40.51Zynlonta $40.30Retevmo $40.06Paxlovid $38.50Amtagvi $34.80Tavalisse $33.47Rezlidhia $33.47Mekinist $33.25
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tariq Mahmood listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.